High doses of pergolide improve clinical global impression in advanced Parkinson's disease—A preliminary open label study
- 31 December 2005
- journal article
- research article
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 41 (3) , 239-253
- https://doi.org/10.1016/j.archger.2005.04.002
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Switching from Bromocriptine to Ropinirole in Patients with Advanced Parkinson's Disease: Open Label Pilot Responses to Three Different Dose-RatiosClinical Neuropharmacology, 2001
- Pergolide monotherapy in the treatment of early PDNeurology, 1999
- Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropiniroleNeurology, 1999
- An Australian multicentre open label study of pergolide as an adjunct to levodopa in Parkinson's diseaseJournal of Clinical Neuroscience, 1996
- High‐dose pergolide monotherapy in the treatment of severe levodopa‐induced dyskinesiasMovement Disorders, 1996
- Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleusThe Lancet, 1991
- Pergolide: A dopamine agonist at both D1 and D2 receptorsLife Sciences, 1991
- Subcutaneous apomorphine in the treatment of Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Treatment of Parkinson's Disease With Pergolide: A Double-Blind StudyMayo Clinic Proceedings, 1988
- ParkinsonismNeurology, 1967